The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | HDAC8: a novel therapeutic target in multiple myeloma
Recent studies have shown that HDAC8, an enzyme responsible for the deacetylation of lysine residues on the N-terminal part of core histones and non-histone proteins, was overexpressed in multiple myeloma cells and was associated with worse survival outcomes. In this video, Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a pre-clinical study investigating the effect of HDAC8 inhibition in multiple myeloma. It was found that HDAC8 inhibition impacted myeloma cell viability and genomic stability, where it led to a decrease in spontaneous DNA breaks and an increase in homologous recombination through inhibition of HDCA8-mediated RAD51 deacetylation. These effects where confirmed in an animal model. In addition, experiments showed that this agent had a synergistic effect in combination with existing multiple myeloma drugs. These findings suggest HDAC8 as a promising therapeutic target in multiple myeloma. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
